Aripiprazole: A treatment for severe coprolalia in "Refractory" Gilles de la Tourette syndrome

Movement Disorders

Volumn 23, Issue 3, 2008, Pages 438-440

  Djebara, Mouna Ben ^a,b,c,d   Worbe, Yulia ^a,b,c,d   Schüpbach, Michael ^a,b,c,d   Hartmann, Andreas ^a,b,c,d  

^a Centre d'Investigation Clinique   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d SORBONNE UNIVERSITÉ   (France)

Author keywords

Aripiprazole; Coprolalia; Gilles de la Tourette syndrome

Indexed keywords

ARIPIPRAZOLE; ETIRACETAM; HALOPERIDOL; PIMOZIDE; RISPERIDONE; ROPINIROLE; TETRABENAZINE; TIAPRIDE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ABSENCE OF SIDE EFFECTS; ADULT; AGGRESSION; ANGIONEUROTIC EDEMA; ARTICLE; CASE REPORT; COPROLALIA; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSKINESIA; DYSTONIA; GILLES DE LA TOURETTE SYNDROME; HUMAN; MALE; OBESITY; OUTCOME ASSESSMENT; PHYSICAL AGGRESSION; PRIORITY JOURNAL; RATING SCALE; SOCIAL BEHAVIOR; TIC; TREATMENT DURATION; TREATMENT RESPONSE; TREATMENT OUTCOME;

ADULT; ANTIPSYCHOTIC AGENTS; HUMANS; MALE; PIPERAZINES; QUINOLONES; TOURETTE SYNDROME; TREATMENT OUTCOME;

EID: 43049180405     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.21859     Document Type: Article

References (15)

1. Cheung MY, Shahed J, Jankovic J. Malignant Tourette syndrome. Mov Disord 2007;22:1743-1750.
2. Cardoso F, Veado CC, de Oliveira JT. A Brazilian cohort of patients with Tourette's syndrome. J Neurol Neurosurg Psychiatry 1996;60:209-212.
3. Teive HA, Germiniani FM, Della Coletta MV, Werneck LC. Tics and Tourette syndrome: clinical evaluation of 44 cases. Ar Qneuropsiquiatr 2001;59:725-728.
4. Stern E, Silbersweig DA, Chee KY, et al. A functional neuroanatomy of tics in Tourette syndrome. Arch Gen Psychiatry 2000;57: 741-748.
5. Gates L, Clarke JR, Stokes A, et al. Neuroanatomy of coprolalia in Tourette syndrome using functional magnetic resonance imaging. Prog Neuropsychopharmacol Biol Psychiatry 2004;29:397-400.
6. Visser-Vandewalle V. DBS in tourette syndrome: rationale, current status and future prospects. Acta Neurochir 2007;97 (Suppl):215-222.
7. Davies L, Stern JS, Agrawal N, Robertson MM. A case series of patients with Tourette's syndrome in the United Kingdom treated with aripiprazole. Hum Psychopharmacol 2006;21:447-453.
8. Yoo HK, Kim JY, Kim CYA. Pilot study of aripiprazole in children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol 2006;16:505-506.
9. Murphy TK, Bengtson MA, Soto O, et al. Case series on the use of aripiprazole for Tourette syndrome. Int J Neuropsychopharmacol 2005;8:489-490.
10. Kastrup A, Schlotter W, Plewnia C, Bartels M. Treatment of tics in tourette syndrome with aripiprazole. J Clin Psychopharmacol 2005;25:94-96.
11. Dehning S, Riedel M, Muller N. Aripiprazole in a patient vulnerable to side effects. Am J Psychiatry 2005;162:625.
12. Nuwer MR. Coprolalia as an organic symptom. Adv Neurol 1982; 35:363-368.
13. Scahill L, Erenberg G, Berlin CM, Jr, et al. Tourette Syndrome Association Medical Advisory Board: Practice Committee. Contemporary assessment and pharmacotherapy of Tourette syndrome. NeuroRx 2006;3:192-206.
14. 2 receptor partial agonist. J Med Invest 2005;52 (Suppl):284-290.
15. Warnock JK, Morris DW. Adverse cutaneous reactions to antipsychotics. Am J Clin Dermatol 2002;3:629-636.